(Q37641043)

21 August 2017

1 reference

title

Endotoxin-binding affinity of sevelamer: a potential novel anti-inflammatory mechanism (English)

1 reference

21 August 2017

0 references

1 reference

Phyllis P Sun

1

1 reference

21 August 2017

Mary C Perianayagam

series ordinal

2

1 reference

21 August 2017

Bertrand L Jaber

series ordinal

3

1 reference

21 August 2017

1 December 2009

1 reference

Kidney International. Supplement

21 August 2017

1 reference

21 August 2017

114

1 reference

21 August 2017

S20-5

1 reference

https://scigraph.springernature.com/pub.10.1038/ki.2009.403

21 August 2017

0 references

cites work

The chemical structure of bacterial endotoxin in relation to bioactivity

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.403

7 January 2021

Targeting bacterial endotoxin: two sides of a coin.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.403

7 January 2021

Inflammation in end-stage renal disease: sources, consequences, and therapy

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.403

7 January 2021

Inflammation and cardiovascular risk in dialysis patients.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.403

7 January 2021

Pathophysiologic quantities of endotoxin-induced tumor necrosis factor-alpha release in whole blood from patients with chronic heart failure

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.403

7 January 2021

The significance of endotoxin release in experimental and clinical sepsis in surgical patients--evidence for antibiotic-induced endotoxin release?

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.403

7 January 2021

Clinical significance of antibiotic endotoxin-releasing properties in trauma patients

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.403

7 January 2021

Use of ultrapure dialysate in reduction of chronic inflammation during hemodialysis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.403

7 January 2021

Clinical significance of translocation

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.403

7 January 2021

Intestinal bacterial microflora--a potential source of chronic inflammation in patients with chronic kidney disease.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.403

7 January 2021

Increased intestinal permeability in patients with Crohn's disease and their relatives. A possible etiologic factor

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.403

7 January 2021

Rho A negatively regulates cytokine-mediated inducible nitric oxide synthase expression in brain-derived transformed cell lines: negative regulation of IKKalpha

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.403

7 January 2021

Crossing barriers: infections of the lung and the gut

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.403

7 January 2021

Endotoxemia after abdominal surgery

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.403

7 January 2021

Experimental radiotherapy-induced enteritis: a probiotic interventional study.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.403

7 January 2021

Modulation of apolipoprotein D expression and translocation under specific stress conditions

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.403

7 January 2021

Effects of protein malnutrition and endotoxin on the intestinal mucosal barrier to the translocation of indigenous flora in mice

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.403

7 January 2021

The effect of route of nutrient administration on the nutritional state, catabolic hormone secretion, and gut mucosal integrity after burn injury.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.403

7 January 2021

The effect of parenteral nutrition on gastrointestinal immunity. The importance of enteral stimulation

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.403

7 January 2021

Nitric oxide and MCP-1 regulation in LPS activated rat Kupffer cells.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.403

7 January 2021

Role of bacterial endotoxin in chronic heart failure: the gut of the matter.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.403

7 January 2021

Increased intestinal permeability to differently sized polyethylene glycols in uremic rats: effects of low- and high-protein diets

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.403

7 January 2021

Impaired intestinal barrier function measured by differently sized polyethylene glycols in patients with chronic renal failure

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.403

7 January 2021

The gastrointestinal tract in uremia

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.403

7 January 2021

The prevalence of symptoms in end-stage renal disease: a systematic review.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.403

7 January 2021

Small intestinal motility

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.403

7 January 2021

Inhibition of the accumulation of uremic toxins in the blood and their precursors in the feces after oral administration of Lebenin, a lactic acid bacteria preparation, to uremic patients undergoing hemodialysis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.403

7 January 2021

Probiotics and prebiotics in dietetics practice

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.403

7 January 2021

Extracorporeal adsorbent-based strategies in sepsis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.403

7 January 2021

Novel dosage forms and regimens for sevelamer-based phosphate binders

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.403

7 January 2021

Sevelamer, a phosphate-binding polymer, is a non-absorbed compound

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.403

7 January 2021

Renagel: reducing serum phosphorus in haemodialysis patients.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.403

7 January 2021

Poly[allylamine hydrochloride] (RenaGel): a noncalcemic phosphate binder for the treatment of hyperphosphatemia in chronic renal failure

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.403

7 January 2021

Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.403

7 January 2021

Effects of sevelamer and calcium-based phosphate binders on uric acid concentrations in patients undergoing hemodialysis: a randomized clinical trial

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.403

7 January 2021

New medications which decrease levothyroxine absorption

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.403

7 January 2021

Effects of sevelamer hydrochloride and calcium acetate on the oral bioavailability of ciprofloxacin

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.403

7 January 2021

Hyperphosphataemia and treatment with sevelamer in haemodialysis patients.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.403

7 January 2021

Effects of sevelamer and calcium-based phosphate binders on lipid and inflammatory markers in hemodialysis patients

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.403

7 January 2021

Sevelamer prevents uremia-enhanced atherosclerosis progression in apolipoprotein E-deficient mice

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.403

7 January 2021

A new era in phosphate binder therapy: what are the options?

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.403

7 January 2021

Inflammatory biomarkers and cardiovascular risk: association or cause and effect?

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.403

7 January 2021

Potential antiatherogenic and anti-inflammatory properties of sevelamer in maintenance hemodialysis patients.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.403

7 January 2021

Endotoxin-binding affinity of sevelamer hydrochloride

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.403

7 January 2021

Sevelamer hydrochloride use and circulating endotoxin in hemodialysis patients: a pilot cross-sectional study.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.403

7 January 2021

Human very low density lipoproteins and chylomicrons can protect against endotoxin-induced death in mice

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.403

7 January 2021

Chylomicrons alter the fate of endotoxin, decreasing tumor necrosis factor release and preventing death

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.403

7 January 2021

Hepatic endosomal trafficking of lipoprotein-bound endotoxin in rats

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.403

7 January 2021

Bile acid binding to sevelamer HCl.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.403

7 January 2021

Identifiers

DOI

10.1038/KI.2009.403

1 reference

Dimensions Publication ID

21 August 2017

1038022330

0 references

Fatcat ID

release_ahfdjvhe45cjbo7s7yodyiwshy

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/ahfdjvhe45cjbo7s7yodyiwshy

24 November 2022

mapped directly with Wikidata item

1 reference